MedTrace Logo

Shanghai Eye Study for Adults

NCT03455478 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000000

Last updated 2022-05-24

No results posted yet for this study

Summary

Blindness and visual impairment severely impact the visual health and life quality of people, particularly the 2.566 million senior citizens aged at 65 and above in Shanghai. The main reason is uncorrected refractive error, of which, 62.1% can be solved through refractive correction. For this reason, the uncorrected refractive errors of 154,000 senior citizens in Shanghai can be taken as a priority among the public health issues to prevent blindness. Now, with the aim to reduce the prevalence rate of blindness and visual impairment, it is planned to establish a public health service mechanism in terms of refractive error screening and correction for the elderly by relying on Shanghai's three-level (city-district-community) eye diseases prevention network, using proper refractive correction technology, and moving related services forward to communities in order to screen, identity, and correct blindness and visual impairment caused by refractive errors as early as possible.

Conditions

  • Blindness,Visual Impairment, Refractive Error, Cataract, High Myopia, Aging

Interventions

DEVICE

spectacles

dispending spectacles for uncorrected refractive error

Sponsors & Collaborators

  • Brien Holden Vision

    collaborator INDUSTRY

  • Shanghai Eye Disease Prevention and Treatment Center

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2019-11-30
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03455478 on ClinicalTrials.gov